ArthroCare Corporation

Refined by:

  • Industry: Healthcare & Medicine   

Sponsored Links

Corporate Profiles

Business Research 17M Companies 21M Executives - Free Trial!

www.OneSource.com

ArthroCare Corp

Coblation - the gentle tonsillectomy procedure.

www.ArthrocareENT.com

News and Blogs

Total : 28 View more »

Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options

www.prnewswire.com

WASHINGTON, July 25 /PRNewswire/ -- Klafter & Olsen LLP has filed a class action lawsuit against ArthroCare Corporation ("ArthroCare" or the "Company") (Nasdaq: ARTC) and certain of its officers in the U.S.

http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/07-25-2008/0004856029&EDATE=

ArthroCare says SEC starts informal inquiry

www.topix.net | Jul 24, 2008

Surgical products maker ArthroCare Corp., which has said it will restate its results going back to 2006, said Thursday it is the subject of an informal inquiry by the Securities and Exchange Commission.

http://www.topix.net/business/medical-equipment/2008/07/arthrocare-says-sec-starts-informal-inquiry

HealthTronics picks up Arlington lab company for $7.5M

www.bizjournals.com | Jul 22, 2008

The acquisition has so far had little impact on HealthTronic's (Nasdaq: HTRN) stock. The company's shares were trading at around $3.20 early Tuesday, down three cents from Monday's close.

http://www.bizjournals.com/austin/stories/2008/07/21/daily15.html?ana=from_rss

Movers roundup: Merck, Schering, Charlotte Russe (AP)

biz.yahoo.com | Jul 21, 2008

Movers roundup: Merck, Schering, Charlotte Russe. - Among the stock activity stories for Monday, July 21, from AP Financial News:

http://biz.yahoo.com/ap/080721/movers_roundup_merck.html?.v=1

Web Sites

Total : 11 View more »

Medical Daily : ArthroCare Launches DoublePlay New Osteoconductive Suture Anchor

ArthroCare Launches DoublePlay New Osteoconductive Suture AnchorFounded in 1993, ArthroCare Corporation is a highly innovative, multi-business medical device company that develops, manufactures and markets minimally ...

http://www.medicaldaily.net/frame_linktop.asp?ID=299966

Video: Stocks to Watch: ArthroCare, Blue Coat Systems, Gibraltar Industries, SemGroup Energy

www.zibb.com

ArthroCare Falls to Lowest Level Since 1990 After Slashing 2006 and 2007 Earnings on "Mistakes"; Blue Coat Systems Raised to "Buy" at ThinkEquity and Pacific Crest Securities; Piper Jaffray Raising Gibraltrar to a "Buy" on Positive Earnings Forecast; Two Investment

http://www.zibb.com/article/3633090/Video+Stocks+to+Watch+ArthroCare+Blue+Coat+Systems+Gibraltar+Industries+SemGroup+Energy+Partners

ArthroCare Corporation

Established in 1993, ArthroCare was originally founded to develop new tools to perform cardiovascular intervention, but quickly expanded the tool set for a variety of soft tissue applications.

http://www.nurses.com/storefronts/arthrocare.html

ArthroCare Corporation

News Resources Jobs Companies Diseases Events Experts News Breaking News By Subject Archive BioBuzz Newsletters Biospace Forums Hotbed Communities Bio NC™ BioCapital™ BioForest™ new BioMidwest™ BioGarden™ (NJ) Biotech Bay™ Biotech Beach™ Genetown™ Pharm Country™ Southern Pharm™ new Career Center

http://www.biospace.net/company_profile.aspx?CompanyId=234404

 

ArthroCare Corporation (ARTC) Corporate Event Announcement Notice - Zibb.com

ArthroCare Corporation (ARTC)
Expected next earnings release:
Announcement date: 9/4/2008 - After Market
Earnings Quarter: Q2
Announcement Status: Unconfirmed

Tags: corporate   earnings   market  

Companies: ArthroCare Corp. (ARTC)

Permalink

 

ArthroCare (ARTC) NewsBite - ARTC Boosted by Upgrade - Zibb.com

ArthroCare (ARTC) was upgraded today by analysts at Lazard Capital and the stock is now at $26.63, up $1.46 (5.78%) on volume of 282,423 shares traded. The brokerage firm upped the stock to "Buy" from "Hold." Over the last 52 weeks the stock has ranged from a low of $19.83 in July to a high of $65.70 in November. ArthroCare stock has been showing support around $23.79 and resistance in the $26.69 range. Technical indicators for the stock are bearish and S&P does not currently have a STARS rating for ARTC. If you are looking for a hedged play on ARTC the stock seems like it could be a candidate for a September out-of-the-money bull-put credit spread below the 17.50 range.

ABR-Seven Summits Strategic Investments NewsBite Goto www.iotogo.com/18w1 for our free report titled, The 18 Ways To Know When It's Time To Dump A Stock

Tags: S&P  

Permalink

 

Zacks Bull and Bear of the Day Highlights: Peabody Energy, Telmex, Concur Technologies, Becton

Zacks Equity Research highlights Peabody Energy (NYSE: BTU) as the Bull of the Day and Telmex ADR (NYSE: TMX) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Concur Technologies (Nasdaq: CNQR), Becton Dickinson (NYSE: BDX) and Cumulus Media (Nasdaq: CMLS).

Full analysis of all these stocks is available at http://at.zacks.com/?id=2676.

Here is a synopsis of all five stocks:

Bull of the Day: Peabody Energy (NYSE: BTU)

Favorable supply and demand fundamentals coupled with Peabody's exposure to seaborne markets should give the company margins and earnings growth above its peers. Its significant unpriced (open position) in '09/'10 will further accelerate revenues, cash flows and earnings as Peabody locks in volumes at prices significantly higher than Q2'08 realizations in the PRB and Illinois Basin, as coal from these areas show continued strength through 2010. We are raising our '08 and '09 estimates from $2.67 to $3.15 per share and from $4.60 to $6.13 per share, respectively.

Bear of the Day: Telmex ADR (NYSE: TMX)

Second quarter 2008 results were disappointing. Net profit was down 13% as revenue fell amid stiffer competition. Moreover, Mexican domestic growth has also stalled. Expansion in other Latin American regions, particularly Brazil, is expected to continue in the near term. Meanwhile, the company still needs to increase the profit margins of its acquired units, which are currently well below that of its Mexican business.

Its valuation seems excessive if compared to other Latin American operators. High inflation and interest rates throughout the world is a matter of huge concern.

Latest Posts on the Zacks Analyst Blog:

Concur Technologies (Nasdaq: CNQR)

Concur Technologies reported results for its second quarter of 2008 that exceeded our revenue and earnings estimates. While Concur has a slightly weaker balance sheet but strong near-term fundamentals, we are concerned about the company's long-term prospects as eventually it will begin to bump heads with the major industry players as it continues to grow at a significant pace.

The company reiterated its commitment to accelerate the pace of re-investments that are intended to sustain the level of revenue growth and innovation in the coming quarters. It rolled out Concur Pay almost six months ahead of schedule, and this has led us to raise our 2008 revenue estimates. We expect revenues and GAAP net income in 2008 to increase by 63.5% and 64.7%, respectively, on a year-over-year basis.

Becton Dickinson (NYSE: BDX)

Becton Dickinson third-quarter results beat our estimates on solid revenue growth and expense management. Declines in selling, general and administrative expense added 170 basis points (bps) to its operating margin, offset by a higher cost of good sold gross margin (60 bps).

For 2008, the management now expects gross margin of 51.2 percent, about 60 bps below the 2007 level. We are increasing our 2008 revenue estimates on the management's updated outlook, and our EPS estimates also increase on greater revenue but with lower operating margin improvement.

Absent acquired growth and FX (foreign currency exchange) benefit, organic revenue growth remains in the 7.0-8.0% area. Acquisitions and other uses of cash, including stock buybacks, will be needed to drive sustainable low double-digit or low teens EPS growth. Nonetheless, the company's diversified and consistent performance is deserving of a premium, in our opinion.

Cumulus Media (Nasdaq: CMLS)

Tightening credit markets and an accelerating industry-wide decline in radio revenue derailed Cumulus Media's buyout deal. Nevertheless, we think the company will again seek to go private when the economy and credit markets improve.

The company is currently trading at 9.0x depressed 2008 EBITDA, well below the former buyout multiple of 14x. Although, we don't expect to see to those previous lofty radio buyout multiples again in light of the industry's secular decline, some multiple expansion would be logical when the economy improves.

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=2649.

About the Bull and Bear of the Day

Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.

About the Analyst Blog

Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2677.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4582.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

SOURCE: Zacks.com

Zacks.com
Mark Vickery
312-265-9380
Visit: www.zacks.com

Read more...

Tags: acquisition   brazil   business   buyout   coal   earnings   ebitda   email   e-mail   energy   eps   expansion   gaap   illinois   interest rates   investment   investment opinion   market   media   nasdaq   net profit   nyse   prices   profit   property   radio   research   revenue   schedule   securities   security   technology  

Companies: Becton, Dickinson & Co. (BDX), Concur Technologies, Inc. (CNQR), Cumulus Media, Inc. (CMLS), Peabody Energy Corp. (BTU), Telefonos de Mexico SA de CV (TMX)

Permalink

 

Holzer Holzer & Fistel, LLC Announces That a Shareholder Class Action Has Been Filed Against

A shareholder class action lawsuit has been filed in the United States District Court for the Western District of Texas against ArthroCare Corporation ("ArthroCare" or the "Company") (NASDAQ: ARTC) and certain of its officers and directors on behalf of purchasers of ArthroCare common stock, who purchased shares between January 24, 2008 and July 18, 2008, inclusive (the "Class Period").

The lawsuit alleges the Company violated the Securities Act of 1934 by making false and misleading statements to the public in its press releases and in its Securities Exchange Commission filings. Specifically, the lawsuit alleges that the Company misstated its revenue and otherwise lacked sufficient internal corporate controls.

If you are a shareholder of ArthroCare common stock with questions concerning your legal rights, you are invited to contact Holzer Holzer & Fistel, LLC and its attorneys Michael I. Fistel Jr., Esq., or Marshall P. Dees, Esq. via email at mfistel@holzerlaw.com, or mdees@holzerlaw.com, or via toll-free telephone at (888) 508-6832.

Holzer Holzer & Fistel, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer Holzer & Fistel, LLC has paid for the dissemination of this promotional communication, and Michael I. Fistel, Jr. is the attorney responsible for its content.

SOURCE: Holzer Holzer & Fistel, LLC

Read more...

Tags: corporate   email   law   lawsuit   legal   nasdaq   revenue   securities  

Companies: ArthroCare Corp. (ARTC)

Permalink